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utoimmune pancreatitis (AIP) is a relatively
new clinical entity whose acceptance as a dis-
tinct systemic disease has grown in the last
decade with the emergence of improved diag-
nostic criteria and management options. AIP has charac-
teristic clinical, radiological, serological, and histological
features (1). A subset of patients with AIP develops
fulminant type 1 diabetes (2,3). The pathogenesis remains
unresolved, but immune-mediated mechanisms that com-
promise endocrine and exocrine pancreatic function ap-
pear to be involved.
Characteristic imaging criteria include pancreatic en-
largement with an irregular, narrow pancreatic duct. The
presence of diffuse swelling and “halo” features on com-
puted tomography appear to be predictors of a favorable
response to treatment with corticosteroids, whereas the
presence of ductal strictures and focal swelling may
predict suboptimal response to corticosteroids, the cur-
rent ﬁrst-line treatment (4). Cases of AIP with focal
enlargement, distinct mass, normal pancreas, and focal
acute pancreatitis have been observed as well as involve-
ment of other organs, such as intrahepatic biliary stric-
tures. Serum IgG or IgG4 levels are elevated in a majority
of cases. Histologic features include the presence of
lymphoplasmacytic sclerosing pancreatitis and inﬁltration
of tissues with IgG4-positive cells (5) (Fig. 1). It is impor-
tant to rule out pancreatobiliary cancer because of overlap
in imaging criteria and other clinical features. The identi-
ﬁcation of a sensitive and speciﬁc biomarker for autoim-
mune pancreatitis detection of autoantibody responses
directed to amylase -2A represents a signiﬁcant advance
for the diagnosis and management of this condition.
While the pathogenesis of AIP and fulminant type 1
diabetes remains to be elucidated, both entities appear to
share pancreatic autoimmune manifestations. A biphasic
mechanism has been proposed recently consisting of
“induction” and “progression” stages (6). An initial induc-
tion response to self-antigens and molecular mimicry is
mediated by decreased naïve regulatory T-cells, and T-
helper cells release proinﬂammatory cytokines. In the
chronic phase, progression is mediated by increased mem-
ory regulatory T- and T–helper cell immune responses.
The classic complement pathway may be activated by the
IgG1 immune complex. A number of important details of
this pathway remain to be elucidated.
In Japanese patients, type 1 diabetes is associated with
the HLADRB1, DQA1, DQB1 *0405, *0303, *0401 or *0901,
*0302, *0303 haplotype (7–9). Interestingly, in this issue of
Diabetes, Endo et al. (10) report that 5 out of 15 patients
with AIP were heterozygous for the HLA DRB1* 0405-
DQB1*0401 haplotype, which conﬁrms previously pub-
lished results in a Japanese population (11,12). It is
noteworthy that a recent study provided convincing evi-
dence that CD4
 T-cells were found to be both necessary
and sufﬁcient for the development of AIP in regulatory
T-cell–deﬁcient, CD28-deﬁcient NOD mice (13). Autoanti-
bodies and autoreactive T-cells from these mice recog-
nized pancreatic amylase, and the administration of
tolerogenic amylase-coupled ﬁxed spleen cells signiﬁ-
cantly improved disease severity, suggesting that this
protein is a signiﬁcant autoantigen in this model of AIP.
A subset of patients with AIP develops fulminant type 1
diabetes. Identiﬁcation of a sensitive and speciﬁc biomar-
ker for this population would represent a signiﬁcant
advance for the diagnosis and management of these indi-
viduals. Endo et al. report that autoantibodies directed
against amylase -2A appear to be a speciﬁc marker for
patients with AIP and fulminant type 1 diabetes. The
authors screened a TriplEx2 human pancreas cDNA
library with serum from a patient with AIP and obtained
positive clones. Subsequently, the authors developed an
enzyme-linked immunosorbent assay (ELISA) to detect
autoantibodies against human amylase -2A using a re-
combinant COOH-terminal amylase -2A protein. Sera
from patients with AIP, chronic alcoholic pancreatitis, and
pancreas tumor were screened, and only the AIP patients
demonstrated autoantibodies that recognized the recom-
binant protein. Of interest, autoantibody against amylase
-2A was detected in 88% of patients with fulminant type 1
diabetes, 21% of patients with acute-onset type 1 diabetes,
and 6% of patients with type 2 diabetes. The authors
conclude that autoantibody against amylase -2A repre-
sents a novel diagnostic marker for both AIP and fulmi-
nant type 1 diabetes. It will be important to determine the
sensitivity and speciﬁcity of the radiobinding assay based
on in vitro transcribed/translated [
35S]methionine-labeled
recombinant amylase -2A, which has been described by
Endo et al. This assay format could be used for large-scale
screening purposes. It is widely known that the overall
performance of ELISA assays detecting autoantibodies
directed to type 1 diabetes–related autoantigens, i.e., insu-
lin or GAD65 autoantibodies, is poor (14).
The clinical and morphological changes that are char-
acteristically observed in patients with AIP and fulminant
type 1 diabetes are nonspeciﬁc. Therefore, the availability
of a speciﬁc serologic biomarker for this disorder would
be very useful, particularly in helping to guide the clinician
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costeroid, relatively early to help preserve pancreatic
exocrine and endocrine function. Based on the data pre-
sented by the authors, the presence of elevated titers of
autoantibodies directed against amylase -2A in the appro-
priate clinical setting may represent a speciﬁc biomarker
to identify patients with AIP and fulminant type 1 diabetes.
The issue of speciﬁcity has been partially addressed by the
observation that sera from patients with either chronic
alcoholic pancreatitis or pancreas tumor did not recognize
the recombinant protein in a ﬂuid-phase assay format.
However, sera from 21% of patients with acute-onset type
1 diabetes and 6% of patients with type 2 diabetes did
demonstrate elevated titers of autoantibody directed
against amylase -2A. Therefore, the speciﬁcity of amylase
-2A autoantibodies as a unique biomarker for AIP and
fulminant type 1 diabetes requires further evaluation and
testing in other racial groups. For example, a recent report
supports the presence of distinct autoantibodies against
exocrine pancreatic antigens in European patients with
type 1 diabetes and nonalcoholic chronic pancreatitis (15).
Autoantibodies against carbonic anhydrase II (CAIIAb)
and lactoferrin (LACAb) (both of which are exocrine
pancreatic antigens) were screened with ELISA. A signif-
icantly higher prevalence of CAIIAb and/or LACAb was
found for patients with type 1 diabetes (29.2%) and nonal-
coholic chronic pancreatitis (22.9%) than in control sub-
jects (0%). There was a signiﬁcant association between
CAIIAb and LACAb titers both for patients with type 1
diabetes (P  0.042) and for patients with nonalcoholic
chronic pancreatitis (P  0.001). Therefore, a subpopula-
tion of European Caucasian patients with type 1 diabetes
and nonalcoholic chronic pancreatitis have autoantibodies
against the exocrine pancreatic antigens CAIIAb and
LACAb. Autoantibodies directed against amylase -2A
were not screened in this report. It is noteworthy that
Endo et al. observed that 100% of the sera from patients
with AIP and 88% of the sera from patients with fulminant
type 1 diabetes demonstrated elevated titers of the auto-
antibody against the recombinant human amylase -2A
protein.
It is unresolved whether the titer of autoantibodies
FIG. 1. Hypothetical mechanisms causing autoimmune pancreatitis. Although the pathogenesis of AIP and fulminant type 1 diabetes remains to
be elucidated, AIP, similar to other autoimmune diseases, is associated with polymorphisms within the HLA complex. In the Japanese population,
the highest risk for autoimmune pancreatitis is conferred by the HLA DRB1*0405-DQB1*0401 haplotype (ref. 11). Each allele is simply given a
number that represents a unique amino acid sequence, and each sequence binds only certain peptides, which could be amylase -2A peptides.
Antigen-presenting cells (APC) present these peptides to lymphocytes and provide signals that stimulate the proliferation and differentiation of
lymphocytes, generally T-lymphocytes. Interestingly, regulatory T-cell–deﬁcient NOD CD28KO mice develop spontaneous AIP, which in this
model is not a consequence of preexisting -cell autoimmunity (ref. 13). This mechanism could also play a role in the pathogenesis of AIP in
humans. The histologic pattern of AIP in humans includes a periductal collar of lymphoplasmacytic inﬂammation (arrows, hematoxylin and eosin
image reprinted with permission from Finkelbert et al. [ref. 16]). MHC, major histocompatibility complex; TCR, T-cell receptor. (Please see
http://dx.doi.org/10.2337/db08-1655 for a high-quality digital representation of this ﬁgure.)
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of the pathophysiology in patients with AIP and fulminant
type 1 diabetes or merely correlates with severity. The
favorable response to intervention with corticosteroids
and the observed decrease in titers of autoantibody sug-
gest that there is an association between the titers of
antibody and severity but do not establish a potential
contributing role for the amylase -2A autoantibodies to
the pathophysiology of this disorder, beyond being a
biomarker for AIP and fulminant type 1 diabetes.
The presence of elevated titers of autoantibodies di-
rected against amylase -2A may represent a novel speciﬁc
biomarker to help identify patients at risk for autoimmune
pancreatitis and fulminant type 1 diabetes. This population
appears to beneﬁt from early intervention with corticoste-
roids, which helps preserve pancreatic exocrine and en-
docrine function. This interesting and potentially clinically
relevant observation requires conﬁrmation by other labo-
ratories and further characterization regarding its speci-
ﬁcity and sensitivity. Mechanistic studies in humans will
be necessary to assess whether there is a pathogenic role
for T-cells and/or autoantibodies reactive with -2A and
whether a combination of speciﬁc T-effector–inactivating
therapies along with immunomodulatory agents can alter
disease course in patients affected by autoimmune
pancreatitis.
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